On June 5, Tunlan Capital and Japan China Korea International Trade reached strategic cooperation in Imperial Hotel Tokyo. Tunlan signed the acquisition agreement on high-end medical service projects. The size of the acquisition and its subsequent investment will surpass 3 billion yen, which will be mainly used for constructions of high-end medical projects and relevant equipment investment.

the signing ceremony

Japan China Korea International Trade is the only official medical service institution of JTB&JMHC high-end physical examinations and regenerative medical treatments authorized by the Japanese Government. It supplies medicine and medical services all over Japan including Tokyo, Osaka, Okinawa, Fukuoka, Kyushu, Hokkaido, etc. Japan China Korea International Trade is able to provide customers with comprehensive and high-quality services including anti-cancer examinations, anti-aging treatments, etc. Based on its mass medical resources and outstanding political and business backgrounds, Japan China Korea International Trade plays an important role in the development of medical treatments and services in various areas, such as stem cells transplantation and plastic surgeries, in the health industry.

Hiruzukurinikku Omotesandou Company concentrates on providing high-end medical services in stem cell transplantation, cancer genetic therapy, high-end physical examinations, drug discovery and development. It has five subsidiary corporations including Hillsclinic Omotesando etc.

According to preliminary statistics, the market size of Chinese overseas medical market has surpassed 100 billion dollars. In recent years, Chinese people become more active in countries with mature medical systems like America, Britain, Singapore and Japan. Such huge size of overseas medical group illustrates two phenomena. First, there are divergences between China and developed countries in dealing with the relationship between professionals and patients, health care and medical treatments, especially in dealing with tumor and cancer. Great hopes were placed on China’s immune therapy, which was regarded as a valuable opportunity for China to catch up with western developed countries in biological medicine. However, due to the influence of the death of Zexi Wei, National Health and Family Planning Commission stopped all clinical applications and increased supervisions on clinical researches of cell immunotherapy. The development of immunotherapy in China suddenly became stagnant.

The second phenomenon is that with the increase of income, more and more people with good economical conditions are looking for better medical resources at worldwide and go abroad to enjoy more developed medical services. Statistics show that in 2014, the number of people in Shanghai who went to other countries to get medical treatment reached 3000. People mainly go abroad to treat serious disease: 80% is cancer; 10% is heart disease; 10% is disorder of the nervous system. In addition, it become more common for patients to go abroad at early the stage of their illness. In some hospitals in America, the cost of medical treatments is close to that in Chinese hospitals. Thus, some people who can afford the cost prefer to get more advanced medical treatments abroad, especially better medical services.

Therefore, we predict that with the increase of the economic level and the change in consumption concepts, the world will accelerate the development in medical services. The market for high-end medical treatments and services looks promising. Japan China Korea International trade is also pushing the expansion of the market. They will together help the development of related business in Japan.

Genetic immunotherapy in Japan stays at the top of international ratings. This cooperation is Tunlan’s new move in the medical field after investments in medical projects in Russia, America and Canada. In the future, Tunlan Capital will use this opportunity to increase the cooperation and investment in Japan and to fully explore the comparative advantages of both Japan and China. Tunlan will contribute towards the developments high-end medical treatments for people in China, Japan and other parts of the world. Tunlan will keep searching advanced medical, manufacturing, new materials, cultural and VR projects and accelerate Tunlan’s economic globalization.

group photo

During this trip to Japan, we also visited Mr. Jianhao Zheng, the president of Ningbo Chamber of Commerce in Japan and gained new insights.